As such, A2AR antagonists are more effective at the hyperoxic phase (i.e. the early stage of ROP), whereas anti-VEGF treatment is more effective at the hypoxic phase (i.e. later stage of ROP, such as ROP stage II-III). The gene discussed is ADORA2A; the disease is retinopathy of prematurity.